SecBot SecBot
8-K ·Filed May 12, 2026

ARVN

ARVINAS, INC.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001628280-26-033875
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The VEPPANU approval is a transformative catalyst, but the revenue cliff and out-licensing to Rigel create uncertainty about the near-term profit trajectory. Watch for HSR clearance on the Rigel deal and initial ARV-806 clinical data in 2026, which could provide the next major pipeline catalyst. The cash runway into 2H 2028 provides a long development horizon.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the completion of large milestone payments from Pfizer. The company posted a GAAP net loss of -$0.90 per share, a sharp reversal from EPS of $1.14 in the prior year. The FDA approval of VEPPANU (vepdegestrant) is a landmark event, but the out-licensing to Rigel Pharmaceuticals and the collapse in reported revenue create a mixed picture for near-term valuation.

Key Financial Metrics

EPS
−$0.90
est −$0.95 · +5.3%
Revenue
$15.6M
est $34.8M · -55.2% · -91.7% YoY
Rating
strong miss

Key Facts

  • Q1 2026 revenue fell 91.7% YoY to $15.6M from $188.8M, driven by the absence of large Pfizer collaboration milestone payments recognized in Q1 2025.
  • GAAP net loss per share was -$0.90, compared to +$1.14 in Q1 2025.
  • FDA approved VEPPANU (vepdegestrant) on June 5, 2026, the first-ever PROTAC drug approval.
  • Arvinas entered into a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU; closing subject to HSR clearance.
  • Cash, cash equivalents, and marketable securities totaled $614.9M as of March 31, 2026, sufficient to fund operations into 2H 2028.
  • ARV-102 Phase 1 data showed >50% LRRK2 degradation in CSF and reduction of key biomarkers in Parkinson's disease patients.
  • ARV-806 completed dose escalation enrollment in Phase 1 for KRAS G12D solid tumors.
  • ARV-393 initiated a Phase 1 combination trial with glofitamab in DLBCL.
  • ARV-027 initiated first-in-human Phase 1 trial in healthy volunteers.
  • ARV-6723 preclinical data presented at AACR; Phase 1 initiation expected mid-2026.

Financial Impact

Revenue collapsed from $188.8M to $15.6M YoY due to the completion of large Pfizer milestone payments. Net loss widened to -$57.6M from net income of $82.9M. Cash burn of $70.5M in the quarter.

revenueepsnet incomecash position

Risk Factors

  • Revenue is highly dependent on collaboration milestones; the Q1 2026 decline shows the volatility of this model.
  • VEPPANU out-licensing to Rigel reduces Arvinas's direct commercial upside and creates execution risk.
  • All pipeline candidates remain in early-stage (Phase 1) clinical trials with no guarantee of success.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-033875
Document: arvn-20260512.htm0001628280-26-033875
Document: 0001628280-26-033875-index-headers.html0001628280-26-033875
Document: 0001628280-26-033875-index.html0001628280-26-033875
Document: 0001628280-26-033875.txt0001628280-26-033875
8-K Data (Synthetic)0001628280-26-033875

Track record

21 reports on ARVN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 Viewing No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026